Oncology News

Oncology

sponsor

Your Unread Messages

Hello, Mary O'connor
Manage E-mail  |  Logout
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ceresoli GL et al. – Second–line therapy in MPM remains an ideal field in which to test new chemotherapy agents as well as new therapeutic strategies, including anti–angiogenic compounds, small molecules or monoclonal antibodies that target different molecular pathways.

Related Articles

Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies
European Journal of Cardio-Thoracic Surgery, 10/14/09    Relevance Score: 80%

Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature
World Journal of Surgical Oncology, 11/12/09    Relevance Score: 68%

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma
The Journal of Thoracic and Cardiovascular Surgery, 10/27/09    Relevance Score: 67%

Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis
Pathology International, 10/20/09    Relevance Score: 67%

A systematic approach to the investigation and diagnosis of a unilateral pleural effusion
International Journal of Clinical Practice, 10/15/09    Relevance Score: 67%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address